Interstitial fluid pressure as an alternate regulator of angiogenesis independent of hypoxia driven HIF-1α in solid tumors

Journal of Orthopaedic Research

Volumn 30, Issue 12, 2012, Pages 2038-2045

  Aung, Khin Zarchi ^a   Pereira, Barry P ^a   Tan, Pamela H S ^a   Han, Hwan Chour ^a   Nathan, Saminathan S ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

angiogenesis; HIF; murine; osteosarcoma; pressure; VEGFA

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE TUMOR; CONTROLLED STUDY; HISTOLOGY; HUMAN; HUMAN CELL; INTERSTITIAL FLUID; MICRO-COMPUTED TOMOGRAPHY; MICROFLUIDICS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; SCID MOUSE; SOLID TUMOR; TIBIA; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANOXIA; CELL HYPOXIA; CELL LINE, TUMOR; EXTRACELLULAR FLUID; GENE EXPRESSION REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; OSTEOBLASTS; OSTEOSARCOMA; PRESSURE; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84867872654     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22154     Document Type: Article

References (26)

1. Lunt SJ, Fyles A, Hill RP, et al. 2008. Interstitial fluid pressure in tumors: therapeutic barrier and biomarker of angiogenesis. Future Oncol 4: 793-802.
2. Jain RK., 1996. Delivery of molecular medicine to solid tumors. Science 271: 1079-1080.
3. Milosevic M, Fyles A, Hedley D, et al. 2001. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res 61: 6400-6405.
4. Fukumura D, Jain RK., 2007. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 101: 937-949.
5. Liao D, Johnson RS., 2007. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 26: 281-290.
6. Carmeliet P., 2003. Angiogenesis in health and disease. Nat Med 9: 653-660.
7. Mizobuchi H, Garcia-Castellano JM, Philip S, et al. 2008. Hypoxia markers in human osteosarcoma: an exploratory study. Clin Orthop Relat Res 466: 2052-2059.
8. Tan C, de Noronha RG, Roecker AJ, et al. 2005. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 65: 605-612.
9. Wu Q, Yang SH, Wang RY, et al. 2005. Effect of silencing HIF-1alpha by RNA interference on expression of vascular endothelial growth factor in osteosarcoma cell line SaOS-2 under hypoxia. Ai Zheng 24: 531-535.
10. Boucher Y, Lee I, Jain RK., 1995. Lack of general correlation between interstitial fluid pressure and oxygen partial pressure in solid tumors. Microvasc Res 50: 175-182.
11. Nathan SS, Huvos AG, Casas-Ganem JE, et al. 2008. Tumor interstitial fluid pressure may regulate angiogenic factors in osteosarcoma. J Orthop Res 26: 1520-1525.
12. Gulliksrud K, Galappathi K, Rofstad EK., 2011. Interstitial fluid pressure and vascularity of intradermal and intramuscular human tumor xenografts. Int J Radiat Oncol Biol Phys 80: 258-264.
13. Rofstad EK, Gaustad JV, Brurberg KG, et al. 2009. Radiocurability is associated with interstitial fluid pressure in human tumor xenografts. Neoplasia 11: 1243-1251.
14. Rofstad EK, Ruud EB, Mathiesen B, et al. 2010. Associations between radiocurability and interstitial fluid pressure in human tumor xenografts without hypoxic tissue. Clin Cancer Res 16: 936-945.
15. Aung KZ, Pereira BP, Leong DT, et al. 2010. VEGF-A expression correlates inversely to the interstitial fluid pressure of human osteosarcoma in a subcutaneous and an orthotopic proximal tibia xenograted SCID mice model. In: 56th annual meeting of the orthopaedic research society, 2010 ed. New Orleans, Louisiana: Orthopaedic Research Society. p 1643.
16. Nathan SS, DiResta GR, Casas-Ganem JE, et al. 2005. Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma. Clin Cancer Res 11: 2389-2397.
17. Zachos TA, Aiken SW, DiResta GR, et al. 2001. Interstitial fluid pressure and blood flow in canine osteosarcoma and other tumors. Clin Orthop Relat Res 385: 230-236.
18. Brekken C, Bruland OS, de Lange Davies C., 2000. Interstitial fluid pressure in human osteosarcoma xenografts: significance of implantation site and the response to intratumoral injection of hyaluronidase. Anticancer Res 20: 3503-3512.
19. Diresta GR, Nathan SS, Manoso MW, et al. 2005. Cell proliferation of cultured human cancer cells are affected by the elevated tumor pressures that exist in vivo. Ann Biomed Eng 33: 1270-1280.
20. Ferrara N, Gerber HP, LeCouter J., 2003. The biology of VEGF and its receptors. Nat Med 9: 669-676.
21. Vaupel P., 2004. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14: 198-206.
22. Vaupel P, Mayer A., 2007. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26: 225-239.
23. Hoogsteen IJ, Marres HA, van der Kogel AJ, et al. 2007. The hypoxic tumour microenvironment, patient selection and hypoxia-modifying treatments. Clin Oncol (R Coll Radiol) 19: 385-396.
24. Goel S, Duda DG, Xu L, et al. 2011. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91: 1071-1121. Review.
25. Nathan SS, Pereira BP, Zhou YF, et al. 2009. Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma. Mol Biol Rep 36: 153-158.
26. Hendriksen EM, Span PN, Schuuring J, et al. 2009. Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumour model. Microvasc Res 77: 96-103.